These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 21440104)

  • 41. Drug delivery to the posterior segment of the eye.
    Thrimawithana TR; Young S; Bunt CR; Green C; Alany RG
    Drug Discov Today; 2011 Mar; 16(5-6):270-7. PubMed ID: 21167306
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Novel composite drug delivery system for honokiol delivery: self-assembled poly(ethylene glycol)-poly(epsilon-caprolactone)-poly(ethylene glycol) micelles in thermosensitive poly(ethylene glycol)-poly(epsilon-caprolactone)-poly(ethylene glycol) hydrogel.
    Gong C; Shi S; Wang X; Wang Y; Fu S; Dong P; Chen L; Zhao X; Wei Y; Qian Z
    J Phys Chem B; 2009 Jul; 113(30):10183-8. PubMed ID: 19572675
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Solid lipid nanoparticles for ocular drug delivery.
    Seyfoddin A; Shaw J; Al-Kassas R
    Drug Deliv; 2010; 17(7):467-89. PubMed ID: 20491540
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Stable drug encapsulation in micelles and microemulsions.
    Narang AS; Delmarre D; Gao D
    Int J Pharm; 2007 Dec; 345(1-2):9-25. PubMed ID: 17945446
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tumoral acidic extracellular pH targeting of pH-responsive MPEG-poly(beta-amino ester) block copolymer micelles for cancer therapy.
    Ko J; Park K; Kim YS; Kim MS; Han JK; Kim K; Park RW; Kim IS; Song HK; Lee DS; Kwon IC
    J Control Release; 2007 Nov; 123(2):109-15. PubMed ID: 17894942
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Amphiphilic methoxy poly(ethylene glycol)-b-poly(ε-caprolactone)-b-poly(2-dimethylaminoethyl methacrylate) cationic copolymer nanoparticles as a vector for gene and drug delivery.
    Yue X; Qiao Y; Qiao N; Guo S; Xing J; Deng L; Xu J; Dong A
    Biomacromolecules; 2010 Sep; 11(9):2306-12. PubMed ID: 20666510
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Polymeric nanoparticulate system: a potential approach for ocular drug delivery.
    Nagarwal RC; Kant S; Singh PN; Maiti P; Pandit JK
    J Control Release; 2009 May; 136(1):2-13. PubMed ID: 19331856
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Drug delivery to the anterior segment of the eye: A review of current and future treatment strategies.
    Mofidfar M; Abdi B; Ahadian S; Mostafavi E; Desai TA; Abbasi F; Sun Y; Manche EE; Ta CN; Flowers CW
    Int J Pharm; 2021 Sep; 607():120924. PubMed ID: 34324989
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In situ gelling systems: a strategy to improve the bioavailability of ophthalmic pharmaceutical formulations.
    Almeida H; Amaral MH; Lobão P; Lobo JM
    Drug Discov Today; 2014 Apr; 19(4):400-12. PubMed ID: 24120893
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Applications of polymeric and lipid nanoparticles in ophthalmic pharmaceutical formulations: present and future considerations.
    Almeida H; Amaral MH; Lobão P; Silva AC; Loboa JM
    J Pharm Pharm Sci; 2014; 17(3):278-93. PubMed ID: 25224343
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ocular disposition, pharmacokinetics, efficacy and safety of nanoparticle-formulated ophthalmic drugs.
    Bu HZ; Gukasyan HJ; Goulet L; Lou XJ; Xiang C; Koudriakova T
    Curr Drug Metab; 2007 Feb; 8(2):91-107. PubMed ID: 17305490
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Stability of an ophthalmic micellar formulation of cyclosporine A in unopened multidose eyedroppers and in simulated use conditions.
    Chennell P; Delaborde L; Wasiak M; Jouannet M; Feschet-Chassot E; Chiambaretta F; Sautou V
    Eur J Pharm Sci; 2017 Mar; 100():230-237. PubMed ID: 28131754
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Non-aqueous formulations in topical ocular drug delivery - A paradigm shift?
    Agarwal P; Rupenthal ID
    Adv Drug Deliv Rev; 2023 Jul; 198():114867. PubMed ID: 37178927
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Drug delivery systems and novel formulations to improve treatment of rare corneal disease.
    Jimenez J; Sakthivel M; Nischal KK; Fedorchak MV
    Drug Discov Today; 2019 Aug; 24(8):1564-1574. PubMed ID: 30872110
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The formulation of drug for ocular administration.
    Aiache JM; el Meski S; Beyssac E; Serpin G
    J Biomater Appl; 1997 Jan; 11(3):329-48. PubMed ID: 9067810
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Oral cyclosporine A--the current picture of its liposomal and other delivery systems.
    Czogalla A
    Cell Mol Biol Lett; 2009; 14(1):139-52. PubMed ID: 19005620
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comment on "Quality by design approach for understanding the critical quality attributes of cyclosporine ophthalmic emulsion".
    Gore A; Attar M; Pujara C; Neervannan S
    Mol Pharm; 2014 Jul; 11(7):2490-2. PubMed ID: 24803420
    [No Abstract]   [Full Text] [Related]  

  • 58. Novel colloidal drug delivery systems.
    Westesen K; Bunjes H; Hammer G; Siekmann B
    PDA J Pharm Sci Technol; 2001; 55(4):240-7. PubMed ID: 11505557
    [No Abstract]   [Full Text] [Related]  

  • 59. Cyclosporin eye drops.
    Boydell P; Ellis S
    Vet Rec; 1993 Mar; 132(13):332. PubMed ID: 8480403
    [No Abstract]   [Full Text] [Related]  

  • 60. [A SIMPLE PROPOSAL FOR THE TREATMENT OF THE ANTERIOR EYE SEGMENT WITH THE CONTINUOUS DROP METHOD].
    NAUMANN G
    Klin Monbl Augenheilkd; 1964 May; 144():597-600. PubMed ID: 14216710
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.